Tag
This study identifies clinicopathologic factors linked to pre- and postoperative levels of circulating tumor HPV DNA (ctHPVDNA) in HPV-mediated oropharyngeal cancer patients treated with upfront surgery, offering insights for disease monito
This clinical analysis of 136 patients highlights that head and neck metastases often serve as the primary manifestation of infraclavicular cancers, emphasizing the diagnostic value of cervical lymph nodes.
The ELAN-RT trial demonstrates that hypofractionated split-course radiotherapy is non-inferior to standard fractionation for 6-month locoregional response in frail older patients, providing a less toxic alternative, though standard therapy
This review analyzes the Phase 3 NIVOPOST-OP trial, demonstrating that adding nivolumab to postoperative chemoradiotherapy significantly improves disease-free survival in high-risk SCCHN patients, establishing a potential new therapeutic st
A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif
This article examines the clinical accuracy of Sentinel Lymph Node Biopsy for head and neck Merkel cell carcinoma, highlighting a significant false-negative rate and identifying risk factors that necessitate more personalized treatment stra
A new study reveals that ‘tumor-informed’ blood tests can detect recurring head and neck cancer months before traditional scans, offering a critical window for intervention in high-risk patients.
Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting l
This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally
A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a
Secondary analysis of three RTOG/NRG trials shows radiotherapy interruptions are associated with higher locoregional failure and worse overall survival in head and neck cancer, with larger absolute harms in p16‑negative and high‑stage disea
A large single-center cohort (n=7,622) shows 12.6% of head and neck cancer patients develop severe (≥RTOG grade 3) radiation-related late toxicities; modifiable factors and specialized multidisciplinary late-effects care may reduce risk and
Longitudinal data from 403 head and neck cancer survivors show that while information and health-system needs decline between years 2 and 5, one-third report at least one moderate-to-high unmet supportive care need at year 5—notably fatigue
A multinational cross‑sectional study of 1,097 head and neck cancer survivors >5 years after diagnosis found that ~50% report moderate‑to‑high unmet supportive care needs, driven by HNC‑specific, psychological and physical/daily living c
A multinational team developed and valued the HNC-8D, an 8-dimension, head and neck cancer–specific health utility instrument derived from EORTC QLQ-C30/H&N43. Valuation in 250 participants yielded mean absolute prediction errors of 0.0
A pooled analysis of two neoadjuvant nivolumab trials found that pathologic treatment effect >57% is associated with markedly improved 3‑year disease‑free and overall survival in HPV‑negative resectable HNSCC, suggesting pTE may be a use
Early palliative care may reduce healthcare costs in head and neck cancer patients using tracheostomy or gastrostomy tubes but does not lessen aggressive hospital care or promote home deaths at the end of life.
This review synthesizes evidence on the timing of palliative care and the use of tracheostomy/gastrostomy tubes in head and neck cancer patients, highlighting their impact on end-of-life costs, quality, and care settings.
An international cohort study developed and externally validated artificial neural networks that stratify older adults with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiation. Models
A multicenter retrospective cohort shows weekly low‑dose cisplatin markedly lowers ototoxicity compared with standard high‑dose every‑3‑week cisplatin in CRT for head and neck squamous cell carcinoma, with similar two‑year survival.
